Welcome to our dedicated page for JOHNSON & JOHNSON SEC filings (Ticker: JNJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Johnson & Johnson filings document the regulatory record for a New Jersey healthcare company with Innovative Medicine and MedTech operations. Recent 8-K reports cover sales and earnings releases, dividend actions, annual meeting voting results and other material corporate events.
The company’s proxy materials describe board elections, executive compensation votes and shareholder governance matters. Its exchange-registered securities include JNJ common stock and multiple NYSE-listed notes with maturities extending across the company’s long-term debt profile.
A shareholder in Johnson & Johnson has filed a notice of proposed sale under Rule 144 for 6,226 shares of common stock. The shares are to be sold through Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate market value of $1,481,195.27.
The seller acquired these shares on 02/05/2026 by exercising a stock option that was originally granted on 02/12/2018, paying the exercise price in cash. The issuer reports 2,409,295,102 shares outstanding, providing context for the size of this planned sale.
The Vanguard Group reports beneficial ownership of 243,455,135 shares of Johnson & Johnson common stock, representing 10.1% of the class as of 01/30/2026.
Vanguard has no sole voting or dispositive power. It has shared voting power over 24,005,159 shares and shared dispositive power over all 243,455,135 shares. The shares are held for clients, who are entitled to dividends and sale proceeds, with no single client holding more than 5% of the class.
Vanguard states the position is held in the ordinary course of business and not to change or influence control of Johnson & Johnson. Following an internal realignment on 01/12/2026, certain Vanguard subsidiaries or business divisions may report beneficial ownership separately while pursuing the same investment strategies as before.
Johnson & Johnson CEO Joaquin Duato reported indirect stock sales by his spouse. On January 26, 2026, the spouse sold 51,218 Johnson & Johnson common shares at a weighted average price of $220.986 per share in multiple trades, and another 48,782 shares at a weighted average price of $221.484 per share.
After these transactions, the filing shows the spouse indirectly holding 79,634 shares and 30,852 shares in two accounts. Joaquin Duato is also shown as directly holding 275,967 common shares and 988 shares through a 401(k) plan as of the plan’s most recent reporting date.
A holder of JNJ common stock filed a notice of proposed sale of 100,000 shares under Rule 144. The shares are to be sold through J.P. Morgan Securities LLC on the NYSE, with an aggregate market value of $22,014,000 based on the figures in the notice. As context, the filing lists 2,409,295,102 JNJ common shares outstanding. The planned sale date is approximately 01/26/2026.
The 100,000 shares of common stock were acquired on 03/18/2025 via a transfer from Joaquin Duoto, who originally received the shares as compensation between 02/12/2021 and 02/13/2023. The form also includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
Johnson & Johnson filed a Form 8-K to share that it has issued a press release announcing its sales and earnings for the fourth quarter and full year ended December 28, 2025. The filing states that the press release is attached as Exhibit 99.1 and covers both quarterly and annual performance.
The company also attached unaudited comparative supplementary sales data and a condensed consolidated statement of earnings for the same periods as Exhibit 99.2. This 8-K centers on making these earnings materials publicly available rather than detailing the specific financial results within the form itself.
Johnson & Johnson, as a reporting person and director of CVRx, Inc., filed an amended Form 4 to correct an earlier insider transaction report. Through its wholly owned subsidiary Johnson & Johnson Innovation - JJDC, Inc., it sold 16,000 shares of CVRx common stock on 11/25/2025 at a weighted average price of $10.03, and 6,337 shares on 11/26/2025 at a weighted average price of $10.03. The shares on 11/25/2025 were sold in multiple trades between $10.00 and $10.22, and on 11/26/2025 between $10.00 and $10.23. After these sales, 4,024,861 CVRx shares were reported as indirectly beneficially owned by Johnson & Johnson through JJDC. The amendment states the 11/25/2025 sale was omitted from the original filing due to an administrative oversight.
Johnson & Johnson director reports deferred share units award
A Johnson & Johnson (JNJ) director reported receiving 185.533 Deferred Share Units (DSUs) on 12/09/2025 at a price of $202.12 per unit. After this transaction, the director beneficially owns 5,058.0682 DSUs in total, held directly.
The DSUs were acquired by deferring the director’s cash retainer under Johnson & Johnson’s Amended and Restated Deferred Fee Plan for Directors. These units will be settled in cash when the director’s board service ends, and each DSU represents the fair market value of one share of Johnson & Johnson common stock on the business day before settlement. The total includes dividend-equivalent rights that accrue on DSUs in line with the company’s quarterly dividend.
Johnson & Johnson director reports deferred share unit award
A Johnson & Johnson (JNJ) director reported receiving 247.378 Deferred Share Units (DSUs) on 12/09/2025 at a price of $202.12 per unit under the company’s Amended and Restated Deferred Fee Plan for Directors. After this transaction, the director beneficially owned 14,153.1187 DSUs in total.
The DSUs represent the fair market value of one share of Johnson & Johnson common stock and are to be settled in cash when the director’s service on the board ends. The holdings also include dividend equivalent rights that accrue on DSUs in line with the company’s quarterly dividend, keeping the director’s deferred compensation aligned with shareholder payouts.
Johnson & Johnson director Daniel E. Pinto reported a compensation-related equity transaction. On 12/09/2025, he acquired 154.611 Deferred Share Units (DSUs) under Johnson & Johnson’s Amended and Restated Deferred Fee Plan for Directors at a derivative security price of $202.12. Following this transaction, he beneficially owned 331.233 DSUs.
The DSUs represent deferred cash retainers and are to be settled in cash when his service as a director ends. Each DSU is tied to the fair market value of one share of Johnson & Johnson common stock on the business day before settlement. The reported balance also includes dividend equivalent rights accrued on DSUs he already held.
Johnson & Johnson director John Morikis reported buying company stock. On 11/26/2025, he acquired 1,250 shares of common stock at a price of $206.15 per share, coded as transaction type "P." After this purchase, he beneficially owned 1,848.51 shares, held directly. The Form 4 indicates the filing relates to one reporting person and shows no derivative securities transactions.